Genentech's California biologics facility will support launches in cancer, neuroscience and more: exec

From modular production equipment and robotics to sustainable building materials, Genentech is pulling out all the stops at its new launch center in Oceanside, California.

Last week, the Roche unit unveiled a $450 million manufacturing investment in Oceanside, some $280 million of which will help fuel the build-out of a new biologics plant designed around sustainability and modular production, Nazeli Dertsakian, vice president and general manager of Oceanside biologics operations at Genentech, said in an interview.